CRDMO Syngene International extended its long-standing strategic collaboration with Bristol Myers Squibb (BMS) through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization, according to Syngene officials.
“Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies,” said Peter Bains, managing director and CEO of Syngene.
“The agreement to extend this partnership through 2035 enables us to plan together for the future in terms of building new capabilities and infrastructure with a decade long horizon. Taking a long-term perspective is a key feature of our partnership which adds strategic value to both companies.”
“At Bristol Myers Squibb, everything we do begins with patients. We greatly value our long-standing partnership with Syngene, which has been instrumental in advancing our scientific ambitions,” added Payal Sheth, senior vice president, therapeutic discovery sciences, Bristol Myers Squibb.
“This expanded collaboration reflects our commitment to advancing innovative science by effective integration of our research, development, and manufacturing capabilities to accelerate the delivery of transformative medicines and bring hope to patients around the world who are waiting for new treatment options.”
The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D Center, which was fully commissioned in 2009. Bains noted that the BBRC has evolved into a major strategic R&D site for Bristol Myers Squibb.
